Addendum
Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100
Report documents
-
Addendum
Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100
Dossier assessment
Indication:
Adult patients with multiple myeloma who have received at least one previous treatment
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-03-16 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A23-09
- Commission
- Commission awarded on 07.02.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed